Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Fig. 1

Genome-wide analyses of 15-year breast cancer-specific survival. The Manhattan plots show the results of the unadjusted analyses (stratified by country). Results are represented as −log10 of the p value from Cox regression models (y-axis). The x-axis shows the chromosome number, where chromosome 23 represents the X chromosome. The red line represents the genome-wide significant threshold 5E−08, the blue line corresponds to the threshold 1E−05. Breast cancer patients included in the analysis in panel: a younger than age 40 years at diagnosis; b diagnosed with a grade 3 tumor; c diagnosed with an ER+ tumor and treated with (any) endocrine therapy; d diagnosed with a ER− tumor and treated with (any) chemotherapy; e diagnosed with an ER+ or PR+, and HER2− tumor; f diagnosed with an ER+ or PR+, and HER2− tumor treated with (any) chemotherapy; g diagnosed with an ER+ or PR+, and HER2− tumor not treated with chemotherapy; h diagnosed with an ER+ or PR+, and HER2+ tumor; i diagnosed with an ER− and PR− and HER2+ tumor; j diagnosed with an ER− and PR− and HER2− tumor; k treated with tamoxifen; l treated with aromatase inhibitor; m treated with CMF-like chemotherapy; n treated with taxanes; o treated with anthracyclines; p all

Back to article page